Published 2023-04-01
“…Blake K Williamson,1 Steven D Vold,2 Anita Campbell,3 Louis Hirsch,4 Deepan Selvadurai,5 Ardalan E Aminlari,6 Jeremy Cotliar,7 Jaime E Dickerson Jnr8,9 1The Williamson Eye Center, Baton Rouge, LA, USA; 2Vold Vision, Fayetteville, AR, USA; 3Grene Vision Group, Wichita, KS, USA; 4Mercy Eye Specialists, Springfield, MO, USA; 5Buffalo Ophthalmology, Williamsville, NY, USA; 6Morris Eye Group, Encinitas, CA, USA; 7Arthur M Cotliar Eye Care and Surgery, New York, NY, USA; 8North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA; 9Sight Sciences, Inc., Menlo Park, CA, USACorrespondence: Jaime E Dickerson Jnr, Email jaime.dickerson@unthsc.eduPurpose: To provide extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study.Setting: Seven multi-subspecialty ophthalmology practices located in 6 states (Arkansas, California, Kansas,
Louisiana, Missouri, and New York).Design: Retrospective, multicenter, IRB approved.Subjects: Eligible eyes had mild–moderate glaucoma and were treated with CP+TR with cataract surgery or as a standalone intervention.Methods: Main outcome measures were mean IOP, mean number of ocular hypotensive medications, mean change in number of medications, proportion of patients with a ≥ 20% reduction in IOP or with IOP ≤ 18 mmHg, and proportion of patients medication free. …”
Get full text
Article